Recent data in murine models of CLL show that PI3Kδ-specific inhibition with idelalisib induces treatment resistance which could be overcome by targeting the insulin-like growth factor 1 receptor (IGF1R) [54]. This evidence concerns the gene IGF1R and B-cell chronic lymphocytic leukemia.